Hansa Biopharma AB (publ) (HNSBF) News Today

→ AI “wealth window” is closing soon! (From Paradigm Press) (Ad)

$2.93

0.00 (0.00%)

(As of 04/17/2024 ET)

Stock Analysis Chart Headlines Short Interest

Source

Source	Headline
	What Wall Street expects from Hansa Medical AB's earnings markets.businessinsider.com - April 17 at 2:34 PM
	Xbrane Biopharma AB XBRANE morningstar.com - April 2 at 11:07 PM
	Hansa Biopharma Expects Strong First Quarter 2024 Sales Performance prnewswire.com - April 2 at 1:32 AM
	Hansa Biopharma publishes 2023 Annual and Sustainability Reports finance.yahoo.com - March 21 at 2:44 AM
	Evan Ballantyne to join Hansa Biopharma as Chief Financial Officer prnewswire.com - February 22 at 9:24 AM
	Hansa Biopharma AB (publ) 2023 Q4 - Results - Earnings Call Presentation seekingalpha.com - February 6 at 1:17 PM
	Hansa Medical AB earnings: here's what to expect markets.businessinsider.com - February 1 at 1:31 PM
	Hansa Biopharma provides update on business and key financials ahead of the JP Morgan Healthcare Conference finance.yahoo.com - January 6 at 9:40 AM
	Hansa Biopharma AB HNSA morningstar.com - December 16 at 6:13 PM
	Imlifidase met primary endpoint in 16-HMedIdes-12 phase 2 trial in patients with AMR following kidney transplantation finance.yahoo.com - December 14 at 8:32 PM
	Imlifidase demonstrated positive safety, tolerability, and early efficacy outcomes in 15-HMedIdeS-09 phase 2 trial in Guillain-Barré Syndrome (GBS) finance.yahoo.com - December 7 at 4:04 AM
	Update on ConfIdeS Phase 3 trial of imlifidase in highly sensitized kidney transplant patients finance.yahoo.com - October 13 at 9:37 AM
	Hansa Biopharma AB: Update on ConfIdeS Phase 3 trial of imlifidase in highly sensitized kidney transplant patients finanznachrichten.de - October 11 at 3:09 PM
	Hansa Biopharma announces encouraging high-level results for first-in-human trial of HNSA-5487 finance.yahoo.com - October 9 at 2:44 PM
	Dr. Hitto Kaufmann appointed Chief Scientific Officer of Hansa Biopharma finance.yahoo.com - September 1 at 9:01 AM
	Hansa Biopharma half year report 2023 finance.yahoo.com - July 20 at 7:39 AM
	First patient treated with imlifidase in an investigator-initiated Phase 2 study in ANCA-associated vasculitis finance.yahoo.com - July 19 at 10:16 AM
	Idefirix (imlifidase) receives provisional approval in Australia as desensitization treatment in highly sensitized patients prior to kidney transplantation finance.yahoo.com - July 11 at 8:17 AM
	Hansa Biopharma to host conference call to provide half year results for January-June 2023 and a Business Update benzinga.com - July 6 at 7:31 AM
	Hansa Biopharma AB recognizes a write-up of SEK 1.430 billion in intangible assets related to Idefirix in the financial statements of the parent company - no impact on the consolidated financials finance.yahoo.com - July 4 at 7:37 AM
	Hansa Biopharma announces positive reimbursement decision for Idefirix (imlifidase) in Belgium as desensitization treatment for highly sensitized patients in kidney transplantation finance.yahoo.com - June 1 at 2:20 AM
	Hansa announces first patient dosed with imlifidase in a global pivotal phase 3 trial in anti-glomerular basement membrane (anti-GBM) disease finance.yahoo.com - May 30 at 4:01 AM
	Hansa Biopharma and Genethon announce collaboration to develop imlifidase as pre-treatment to gene therapy in Crigler-Najjar syndrome patients with anti-AAV antibodies finance.yahoo.com - April 27 at 1:41 PM
	Hansa Biopharma provides Q1 update msn.com - April 20 at 8:08 AM
	Hansa Biopharma interim report January-March 2023 finance.yahoo.com - April 20 at 3:07 AM
	Hansa Biopharma AB (publ) (0RC7.IL) ca.finance.yahoo.com - March 30 at 1:37 PM
	Hansa Biopharma announces positive reimbursement decision in Spain for Idefirix® (imlifidase) as desensitization treatment for highly sensitized patients in kidney transplantation finance.yahoo.com - March 29 at 12:32 PM
	Matthew Shaulis appointed Chief Commercial Officer and US President of Hansa Biopharma finance.yahoo.com - March 3 at 4:58 AM
	Hansa Biopharma AB (publ) (HNSA.ST) finance.yahoo.com - February 10 at 1:13 PM
	Hansa Biopharma Year-end report January-December 2022 finance.yahoo.com - February 2 at 7:57 AM
	Hansa Biopharma announces positive reimbursement decision for Idefirix® (imlifidase) in the Czech Republic finance.yahoo.com - January 2 at 9:39 AM
	Hansa Biopharma announces positive reimbursement decision in Italy for Idefirix® (imlifidase) as desensitization treatment for highly sensitized patients in kidney transplantation finance.yahoo.com - December 8 at 7:01 AM
	Hansa Biopharma announces positive topline data from the imlifidase phase 2 study in antibody mediated rejection (AMR) episodes post kidney transplantation finance.yahoo.com - November 28 at 8:11 PM
	Hansa Biopharma and partner Sarepta Therapeutics plan to initiate a clinical study with imlifidase as a pre-treatment to Sarepta's SRP-9001 gene therapy in DMD in 2023 finance.yahoo.com - November 3 at 2:42 AM
	Hansa Biopharma Interim report January-September 2022 finance.yahoo.com - October 20 at 3:54 AM
	Hansa Biopharma: Increase of the number of shares and votes finance.yahoo.com - September 30 at 4:22 PM
	Hansa Biopharma to host conference call to provide interim results for January-September 2022 and Business Update finance.yahoo.com - September 30 at 6:21 AM
	UBX Unity Biotechnology, Inc. seekingalpha.com - September 20 at 8:57 PM
	The Scottish Medicines Consortium (SMC) recommends use of Hansa Biopharma's Idefirix[®] (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients finance.yahoo.com - September 12 at 10:36 AM
	Hansa Biopharma: Issue and repurchase of class C shares for incentive programs finance.yahoo.com - September 9 at 4:25 PM
	Hansa Biopharma and Medison Pharma announce positive reimbursement decision in Poland for Idefirix® in highly sensitized kidney transplant patients finance.yahoo.com - August 22 at 1:07 PM
	European Society for Organ Transplantation's (ESOT) guidelines for desensitization treatment of highly sensitized kidney transplant patients published in Transplant International finance.yahoo.com - August 10 at 4:10 AM
	Here's what to expect from Hansa Medical AB's earnings markets.businessinsider.com - July 19 at 3:24 AM
	Hansa Biopharma half year report 2022 finance.yahoo.com - July 19 at 3:24 AM
	Hansa Biopharma announces $70 million non-dilutive product finance transaction with NovaQuest to support continued development of the company's antibody-cleaving enzyme technology platform finance.yahoo.com - July 18 at 5:20 PM
	Hansa Biopharma announces first patient treated in the post-authorization efficacy study (PAES) of Idefirix® (imlifidase) in highly sensitized kidney transplant patients finance.yahoo.com - July 11 at 5:04 AM
	The FDA accepts BLA and grants priority review for lecanemab for treatment of early Alzheimer's disease under the accelerated approval pathway yahoo.com - July 6 at 2:01 AM
	NICE recommends use of Hansa Biopharma's Idefirix® (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients finance.yahoo.com - June 16 at 4:52 AM
	Hansa Biopharma AB's (HNSBF) CEO Søren Tulstrup on Q1 2022 Results - Earnings Call Transcript seekingalpha.com - April 21 at 6:34 PM
	Hansa Biopharma interim report January - March 2022 finance.yahoo.com - April 21 at 8:34 AM

Get Hansa Biopharma AB (publ) News Delivered to You Automatically

AI “wealth window” is closing soon! (Ad)

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

I put together this personal video [HERE]…

HNSBF Media Mentions By Week

HNSBF Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

HNSBF
News Sentiment
▼
0.00

0.40
▲
Average
Medical
News Sentiment

HNSBF News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

HNSBF Articles
This Week
▼
1

0
▲
HNSBF Articles
Average Week

Get Hansa Biopharma AB (publ) News Delivered to You Automatically

Related Companies and Tools

Related Companies:

Headlines Tools:

This page (OTCMKTS:HNSBF) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Hansa Biopharma AB (publ) (HNSBF) News Today

HNSBF Media Mentions By Week

HNSBF Media Sentiment

HNSBF News Coverage

Related Companies and Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info